ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Tablets USP
(Baudette, MN) — Sept. 12, 2023 — ANI Pharmaceuticals, Inc. announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Estradiol Tablets USP. ANI’s Estradiol Tablets USP are the generic version of the Reference Listed Drug (RLD) Estrace®. The According to IQVIA, a leading healthcare data and analytics provider, the current annual U.S. market for Estradiol Tablets USP is approximately $40.9